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Brief Clinical Reportscirculation. If it is, then an SVAD should improve the overall
circulation. However, if the left ventricular end-diastolic
pressure is not high, then an SVAD is unlikely to improve he-
modynamics. If the pulmonary circulation is primarily re-
sponsible for hemodynamic deterioration, then insertion of
a VAD at a subpulmonary position is an option.2 Much ani-
mal and computer modeling has been done to study the pos-
sibility of mechanically augmenting pulmonary blood flow
in the Fontan baffle.5
The lack of a subpulmonary ventricle in the Fontan phys-
iology may result in suboptimal filling of an SVAD. There-
fore, we believe that it is important to ensure almost
complete systemic ventricular decompression by setting
the HeartMate II SVAD at higher revolutions per minute
to encourage passive flow into the pulmonary arteries.
Also, with a single ventricle, unlike in a biventricular heart,
there is little concern, even at high revolutions per minute,
of jeopardizing output of the pulmonary ventricle by shift-
ing of the intraventricular septum. With these settings, cen-
tral venous pressure decreased significantly with adequate
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uted to the improvement in his PLE.
This is the first report of successfully discharging home
a patient who has a failing Fontan circulation with an im-
plantable VAD. Given the increasing cohort of adults and
children with failing Fontan circulations, this case repre-
sents a significant evolution in therapy for single ventricle
patients who will increasingly be receiving SVADs not
only for support to transplant but also perhaps to destination.References
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Thorac Surg. 2009;88:170-6.The use of the HeartWare HVAD for long-term right ventricular
support after implantation of the HeartMate II deviceJohn M. Stulak, MD, Kevin E. Griffith, John M. Nicklas, MD, and Francis D. Pagani, MD, PhD,
Ann Arbor, MichBiventricular support is required in approximately 6%
to 30% of patients undergoing implantation of left ventric-
ular assist devices (LVADs).1 Although the routine applica-
tion of a reliable, long-term implantable right ventricular
assist device (RVAD) remains elusive, use of the Heart-
Ware HVAD (HeartWare International, Inc, Framingham,
Mass) and Jarvik 2000 (Jarvik Heart, Inc, New York,
NY) for long-term totally implantable biventricular
support has been reported.2,3 Although the only reports
in existence detail the use of 2 HeartWare HVADs forbiventricular support, we report the use of this device
for right ventricular support after implantation of
a HeartMate II LVAD (Thoratec Corporation, Pleasanton,
Calif).CLINICAL SUMMARY
A 59-year-old African American woman with nonische-
mic cardiomyopathy and congestive heart failure was seen
with acute, decompensated heart failure and rapidly deteri-
orating condition. After evaluation, the patient underwent
emergency HeartMate II and CentriMag RVAD (Thoratec)
implantation for biventricular failure. Postoperatively, the
patient had several failed attempts at RVAD weaning and
was subsequently listed status 1A for heart transplant. After
transplant workup, numerous antibodies with a high panel-
reactive antibody titer were noted, and the patient underwent
several rounds of plasmapheresis, intravenous immune
globulin, and bortezomib (Velcade). Despite these interven-
tions, transplant was essentially excluded as a result of
significant persistent allosensitization. An appeal was
subsequently made for compassionate use of the HeartWaregery c September 2011
FIGURE 1. A,Anterior protrusion of implantedHeartWareHVAD.B,Bilateral pectoralis flap closure after partial sternectomy. C, Prerelease chest radiograph.
Brief Clinical ReportsHVAD for permanent right ventricular support. After ap-
proval, the patient underwent resternotomy, removal of the
CentriMag RVAD (after 303 days of support), and place-
ment of the HeartWare HVAD. Under cardiopulmonary by-
pass, the device was placed through an anterior right
ventriculotomy in proximity to the right ventricular outflow
tract. The previously placed HeartMate II LVAD was left
undisturbed. After start-up of both devices, the patient was
weaned from cardiopulmonary bypass, with device support
incrementally increased in tandem. Final pump speed for the
HeartWareHVADwas2400 rpm(flow3.5L/min); that for the
HeartMate II LVAD was 9000 rpm (4 L/min). Because of
anterior location of the HeartWare HVAD, a partial sternec-
tomy was required with temporary closure (Figure 1, A). A
plastic surgeon then performed bilateral pectoralis flap clo-
sure on postoperative day 3 (Figure 1, B).
The patient was released from the hospital on postop-
erative day 28 after HeartWare HVAD placement (hospi-
tal day 331 after HeartMate II device insertion). The
prerelease chest radiograph is shown in Figure 1, C. At
6-month follow-up, renal function and laboratory values
are within reference ranges, and the patient has excellent
functional capacity with minimal symptoms. There has
been no evidence of hemolysis, and no changes have
been made to pump speed settings and flows on either
device.The Journal of Thoracic and CarDISCUSSION
This case highlights the challenges involved when
patients require mechanical left ventricular support but
have concomitant right ventricular failure. If transplant is
not an option, there is no reasonable alternativewithout a re-
liable, long-term RVAD. Although therapy is individual-
ized, we are extremely selective before proceeding with
assist device implantation in patients with poor right ven-
tricular function who are not transplant candidates. The pa-
tient described here was initially thought to be a transplant
candidate before LVAD implantation; however, transplant
was ruled out postoperatively because of sensitization.
This case also raises several important technical issues
when using the HeartWare HVAD in the role of RVAD. Be-
cause the HeartWare HVAD was designed to interact with
systemic resistance and not with the lower pulmonary resis-
tance, important modifications are required. First, because
the HeartWare HVAD is afterload sensitive, lower pump
speed or outflow graft restriction is mandatory. Narrowing
the outflow graft brings the low pulmonary vascular resis-
tance closer to that of the systemic circulation; this is
achieved by suturing a 3-cm long segment with 6-0 Prolene
suture (Ethicon, Inc, Somerville, NJ) over a 5- to 7-mm He-
gar dilator (Figure 2, A).2 A patient with high pulmonary
vascular resistance may require less restriction, and without
a restrictor the lower pulmonary resistance may requirediovascular Surgery c Volume 142, Number 3 e141
FIGURE 2. A, Outflow graft is restricted close to the HeartWare HVAD (arrow). B, Additional felt rings are used to decrease the intracavitary length of the
inflow cannula.
Brief Clinical Reportspump speed to approach the lower operating limit of 1800
rpm. Implications include (1) lower accuracy of estimated
flow at lower speeds, (2) less ability to correct suction con-
ditions by lowering pump speed, and (3) increased potential
for pump thrombosis or rotor instability. Second, the Heart-
Ware HVAD inflow cannula length was designed for place-
ment through the left ventricular apex and is not optimized
for the right ventricle. Shortening the length of the inflow
cannula to accommodate the shallower right ventricular
cavity in the right ventricular outflow tract is achieved by
placing additional felt rings under the fixation ring
(Figure 2, B). Other locations that may potentially allow
normal chest closure include placement into the right atrium
or the diaphragmatic surface of the right ventricle.
For this patient, the goals for pump flows were 3 to
4 L/min through the RVAD and 5 to 6 L/min throughFrom the Department of General and Cardiothoracic Surgery, Graduate School of
Medicine, Gifu University, Gifu, Japan.
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rin and warfarin sodium, with an international normal-
ized ratio goal of 2 to 3. We were successful in this
case; however, this is the first report of HeartWare
HVAD use in the role of RAVD after HeartMate II im-
plantation. Firm recommendations regarding the poten-
tial widespread applicability of this therapy are
therefore limited.
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Maker: a case report. J Thorac Cardiovasc Surg. 2004;128:625-6.Complete resection of asymptomatic solitary right atrial metastasis
from renal cell carcinoma without inferior vena cava involvementNarihiro Ishida, MD, PhD, Hirofumi Takemura, MD, PhD, Katsuya Shimabukuro, MD, PhD, and
Yukihiro Matsuno, MD, PhD, Gifu, JapanMetastatic cardiac tumors are considered a terminal state
of primary malignancy. Therefore, the condition of patients,
local recurrence, and other metastases should be considered
regarding indications for surgery, which should aim toimprove the prognosis of patients in good condition with
malignancies and prevent concomitant critical events.CLINICAL SUMMARY
A 61-year-old woman was referred to the Graduate
School of Medicine with an incidentally discovered right
atrial tumor. She had undergone radiotherapy and chemo-
therapy to treat bone metastasis after left nephrectomy for
renal cell carcinoma and radical hysterectomy for uterine en-
dometrial adenocarcinoma 1 year previously andwas free of
symptoms originating from the heart. A computed tomogra-
phy examination for femoral pain revealed a cardiac tumor
(Figure 1, A) without findings in the femur. Subsequentgery c September 2011
